ChiCTR2000035131 版本V1.3 版本创建时间2020/08/01 22:36:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000035131 

最近更新日期:

Date of Last Refreshed on:

2020-08-01 22:34:26 

注册时间:

Date of Registration:

2020-08-01 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

CD5L在创伤相关ARDS的变化及其临床意义

Public title:

Change and clinical significance of CD5L in trauma-associated-ALI/ARDS

注册题目简写:

English Acronym:

研究课题的正式科学名称:

CD5L作为创伤相关急性肺损伤或急性呼吸窘迫综合征的生物标志物及其预测价值

Scientific title:

Predictive value of elevated serum levels of CD5L in acute lung injury and acute respiratory distress syndrome following trauma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

程倩 

研究负责人:

罗艳 

Applicant:

Cheng Qian 

Study leader:

Luo Yan 

申请注册联系人电话:

Applicant telephone:

+86 18883938295

研究负责人电话:

Study leader's telephone:

+86 13883143775

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

18883938295@163.com

研究负责人电子邮件:

Study leader's E-mail:

LuoYan476534@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

重庆市渝中区友谊路1号

研究负责人通讯地址:

重庆市渝中区友谊路1号

Applicant address:

1 Youyi Road, Yuzhong District, Chongqing

Study leader's address:

1 Youyi Road, Yuzhong District, Chongqing

申请注册联系人邮政编码:

Applicant postcode:

400016

研究负责人邮政编码:

Study leader's postcode:

400016

申请人所在单位:

重庆医科大学附属第一医院

Applicant's institution:

The First Affiliated Hospital of Chongqing Medical University

研究负责人所在单位:

重庆医科大学附属第一医院

Affiliation of the Leader:

The First Affiliated Hospital of Chongqing Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020-348

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

重庆医科大学附属第一医院伦理委员会

Name of the ethic committee:

The Institutional Research Ethics Committee of the First Affiliated Hospital of Chongqing Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-22 00:00:00

伦理委员会联系人:

严青

Contact Name of the ethic committee:

Yan Qing

伦理委员会联系地址:

重庆医科大学附属第一医院5号楼A栋11楼

Contact Address of the ethic committee:

11st Floor, Building 5-A, 1 Youyi Road, Yuzhong District, Chongqing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 023-89011876

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

重庆医科大学附属第一医院

Primary sponsor:

The First Affiliated Hospital of Chongqing Medical University

研究实施负责(组长)单位地址:

重庆市渝中区友谊路1号

Primary sponsor's address:

1 Youyi Road, Yuzhong District, Chongqing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

重庆

市(区县):

Country:

China

Province:

Chongqing

City:

单位(医院):

重庆医科大学附属第一医院

具体地址:

渝中区友谊路1号

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Address:

1 Youyi Road, Yuzhong District

经费或物资来源:

国家自然科学基金青年科学基金项目

Source(s) of funding:

Youth Program of National Natural Science Foundation of China

Target disease:

trauma

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

为了确定最初的CD5L作为创伤第一天同时也是入院第一天创伤相关急性肺损伤或急性呼吸窘迫综合征的潜在生物标志物,同时研究CD5L是否为创伤相关急性肺损伤或急性呼吸窘迫综合征的独立危险因素之一。  

Objectives of Study:

To determine the utility of apoptosis inhibitor of macrophage (AIM)/CD5L as a potentially biomarker of trauma associated-ALI/ARDS on emergency department (ED) arrival, and to analysis its impact on trauma-related acute lung injury or acute respiratory distress syndrome.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄:16-80岁;
2. 男女不限;
3. ICU或骨科住院者(创伤发生后24h 内入院患者);
4. 患者签署知情同意书。

Inclusion criteria

1. Aged 16-80 years;
2. Male or female;
3. Emergency department admissions (patients admitted within 24h after trauma);
4. Patient signs informed consent.

排除标准:

1. 再次住院的患者;
2. 有慢性间质性肺病病史或被诊断为充血性心力衰竭的患者;
3. 患有癌症肺炎,肝纤维化,特应性皮炎的自身免疫性疾病(例如类风湿性关节炎,系统性红斑狼疮,牛皮癣和银屑病关节炎),皮肤病,慢性根尖周炎和糖尿病;
4. 精神疾病患者;
5. 孕妇;
6. 不愿意合作或沟通有障碍患者。

Exclusion criteria:

1. Patients who were rehospitalized;
2. Patients had a history of chronic interstitial lung disease or were diagnosed with congestive heart failure;
3. Patients with cancer, pneumonia, liver fibrosis, atopic dermatitis autoimmune disease (such as, rheumatoid arthritis, systemic lupus erythematosus, psoriasis and psoriatic arthritis), skin disease, chronic apical periodontitis and diabetes mellitus;
4. Patients with mental illness;
5. Pregnant woman;
6. Patients who are unwilling to cooperate or have communication barriers.

研究实施时间:

Study execute time:

From 2020-07-24 00:00:00 To 2020-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2020-07-25 00:00:00 To 2021-08-31 00:00:00  

干预措施:

Interventions:

组别:

创伤相关ARDS组

样本量:

81

Group:

trauma associated-ALI/ARDS group

Sample size:

干预措施:

干预措施代码:

none

Intervention:

none

Intervention code:

组别:

单纯创伤组

样本量:

46

Group:

isolated trauma group

Sample size:

干预措施:

干预措施代码:

none

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

重庆 

市(区县):

 

Country:

China 

Province:

Chongqing 

City:

 

单位(医院):

重庆医科大学附属第一医院 

单位级别:

三级甲等 

Institution
hospital:

The First Affiliated Hospital of Chongqing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

CD5抗原样蛋白

指标类型:

主要指标

Outcome:

CD5 antigen-like protein

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

全血

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 16 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

就诊于我院急诊科的所有创伤患者均可入组,但需通过入组及排除标准进行筛选。

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients admitted to the emergency room of our hospital with the diagnosis of traumatic injury, presenting within 24 hours of injury are considered to be enrolled in our study.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

N/A

Blinding:

N/A

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

拟于文章发表后6个月内公开原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The statistical data and results will been uploaded within six mouths after the munuscript published in this websites.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2020-08-01 15:31:56